Home » OCTOPLUS ANNOUNCES LOCTERON STUDY RESULTS
OCTOPLUS ANNOUNCES LOCTERON STUDY RESULTS
OctoPlus has reported the results of a Phase I study with Locteron, the company's controlled-release formulation of alfa interferon for the treatment of chronic hepatitis C.
Phase I results show that a single dose of Locteron delivered to healthy volunteers is safe and results supported that Locteron could be effectively dosed once every two weeks, which is a substantial improvement over the current pegylated interferons that require dosing every week
Locteron is designed to be a best-in-class therapeutic for patients with chronic hepatitis C, and has the potential to induce less side effects and to increase therapeutic efficacy and patient compliance compared with current therapies.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May